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The Effect of FK 506 and Cy A on the Lewis Rat Renal Ischemia Model 
MA Nalesnik. H.S. lai. N. Murase. S. Todo. and T.E. Starzl 
THE new immunosuppressant FK 506 shows great promise as a powerful means of inducing long-term 
allograft acceptance In a clinical selling. fI~ This drug has 
been shown to be several hundred times more potent than 
Cy A in its immunosuppressive effects. 1./0 In vitro and in 
vivo studies have also shown synergism between the 
actions of FK 506 and CyA. H.7 The exact basis of this 
synergism has not yet been elucidated: however. it is 
known that both drugs inhibit T cell response at the level of 
IL-2 production and recognition. 1.6.K.9 
Since these agents may have similar pharmacologic 
actions. we explored the possibility that they might share 
similar toxicities. One well-known side effect of CyA 
administration IS nephrotoxicity. which can occur in acute 
Of chronic formsKfEf-f~ The acute form of nephrotoxicity 
can be exacerbated by concomitant warm ischemia in the 
case of renal transplantation. J.I 
The purpose of this study was to analyze the effect of 
FK 506 on the ischemic kidney in a rat model. We 
hypothesized that the drug would show effects similar to 
that seen with CyA. Further. we considered the possibility 
that the coadministration ofCyA and FK 506 to the acutely 
ischemic kidney could have additive toxicity. Such syner-
gistic toxicity would have implications for the use of this 
combination of drugs in the early management of renal 
transplant patients. 
MATERIALS AND METHODS 
Antmals 
~ale Inbred LeWIS rats (RTI') weIghing :!PR-~RR g were purchased 
from Harlan Sprague-Dawlev. Indianapolts. IN. 
PharmacologiC Agents 
FK 506 crystalline powder was supplied by Fujisawa Pharmaceu-
tIcal Company. Osaka. Japan. It was dissolved in 9.9% sodIum 
chloride for oral admlnistratton. 
eyA (Sandoz. Ltd. Basal. Switzerland) was obtained in the 
commercial formulauon (100 m(Zlmit. It was diluted in olive oil for 
oral admlnistrauon. 
SurgIcal Procedure 
Antmals were aneslhettzed with penlObarbnal. 40 m(Zlkg intraper-
lIoneallv. A mIdline abdominal inCIsion was made followed by 
Inruslon of hepann. 50 IU intravenouslv. The nghl penrenal faSCIa 
was dIssected free. !cavin!! onlv the pedIcle of vessels and ureter. 
The nght renal anerv was Idenutied. and was clamped 10 Induce 
Ischemia. The clamp was removed 60 minutes later. Immediatelv 
followln!l revasculanzauon of the nght kidney. a left nephrectomy 
was pen'ormed. 
Experimental Groups 
All animals underwent 60 minutes of right renal ischemia followed 
oy left nephrectomy. They were then random Iv assIgned to the 
following groups: A tn = 41. no treatment: B tn '" 5). FK 506 I 
mglk(t/d orally: C tn = 51. FK 506 2 mglk(t/d orally: D tn '" 41. FK 
S064 m(t/kgld orally: E tn '" 51. CyA 5 mglk(t/d orally: F tn '" 5l. 
CyA 10 m(t/kgid orally; G tn '" 5). CyA 25 m(t/k(Zld orally: and H 
tn = 5). FK 506 I mglkgld and CyA 10 m(t/kgld orally. All animals 
were killed on day 10. 
Three additional groups underwent the above operation. had 
renal biopsies performed on day 2 for electron mIcroscopy. and 
were killed on day 5. These groups were as follows: I (n '" 5l. no 
treatment: J tn '" 51. FK 506 4 mglkgld orally: and K tn '" 5l. CyA 
~R mglkgld orally. 
Measurements and Statistical Analysis 
Antmals were examined and wel!lhed dally. Blood samples for 
blood urea nmogen (8 UN) and creallnme were collected vIa tall 
vein on days I. 2. 3. 5. 7. and 10. Data were analyzed uSing 
one-way analysis of vanance followed by pair-WIse comparisons 
using the least significant difference test at a value of P < 0.05, 
Histologic variables at day 10 were subjectively scored. Ultra-
structural and histologic features at days 2 and 5 were subjectively 
compared. 
RESULTS 
All animals survived the operative procedure. Group A 
animals maintained a normal level of activity during the 
experimental period. Rats in the Cy A and FK 506 treat-
ment groups appeared somewhat emaciated. with a mod-
erate degree of hair loss. Postoperative weight loss oc-
curred in all groups. The mean maximum weight loss in the 
control group (AI was 15%. whereas In the expenmentaJ 
groups it ranged from 23-27%. 
Mean levels of serum creatinine are given In Table I. A 
graphic representation of the time courses of these mean 
levels in the high-dose groups is shown in Fig I. Both CyA 
and FK 506 were associated with significantly elevated 
creatinine levels when compared with controls. The high-
est elevations occurred on the first day and levels dropped 
progressively thereafter. At 25 mglkgld Igroup Gl_ CyA 
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Table 1. Serum Cl'MtInlne Level. of Varioua Group. Over a lo-Day Period Following InductIOn of Renaillchemia 
droumE~dF Davo Day 1 Dav2 Dav3 DayS Dav 7 Dav 10 
A (control) 1.0!: .09 2.2!: .29 1.8!: .26 1.3!: .14 1.1 !: .08 1.0!: .09 1.0 !: .06 
B (FK 506 1) 1.0!: .02 2.9!: .20 2.1!:.21 1.7!:.14 1.7!:.13 1.3 !: .05 1.1 !: .03 
C (FK 506 2) 1.0:!: .04 3.0!: .28 2.8 !: .28 2.1 !: .17 1.3!: .14 1.1 :!: .03 1.1 :!: .03 
D (FK 506 4) 1.2!: .06 3.2 !: .31 2.8!: .42 2.3!: .33 2.1 :t .23 1.3!: .09 1.2!: .03 
E (eyA 5) 1.2!: .05 2.4 !: .08 1.9 :!: .11 1.7:!: .10 1.5!: .10 1.3:!: .06 1.1 :!: .03 
F (eyA 10) 1.2!: .05 2.8!: .31 2.3:!: .24 2.0!: .29 1.7!:.10 1.6:!: .07 1.2!: .06 
G (CyA 25) 1.2!: .05 4.9!: .26 4.8:!: .46 4.2!: .11 2.2:!: .24 1.4:t .22 1.0:!: .08 
H (FK 506 1 + eyA 10) 1.3!: .00 3.8:!: .13 2.7:!: .16 2.5:!: .14 1.7!:.14 1.0:!: .04 0.9:!: .06 
Note: Values are •• preaecla mean ~ SEM. 
was associated with the highest initial serum creatinine 
level. In general. enzyme levels increased as drug dosage 
increased. No clear-cut differences emerged between low-
dose FK 506 compared with low-dose CyA in regard to 
degree of creatinine elevation (calculations not shown). 
The early rise in serum creatinine that occurred in 
animals given combination FK 506 I mg/kg/d and CyA 10 
mgikgld (group Hl was greater than that seen when the 
drugs were given alone (groups B and Fl. However. the 
levels dropped down to normal in all groups by day JO. 
In same general trends were observed in analysis of 
BUN levels (data not shown). 
HistologiC Analysis 
Tissue for ultrastructural analysis was available from 
groups I. J. and K on day 2: both light and ultrastructural 
studies were performed on these groups on day 5. Tissue 
for light microscopy was available from the remainder of 
animals killed on day 10. 
Control tissue from day 2 showed a moderate degree of 
cytoplasmic vacuolization. located predominantly near the 
luminal surface. Although this may have arisen in some 
areas from dilated endoplasmic reticulum. it appears to 
also have been related to numerous small microvesicles 
that were observed to arise from the cell membrane 
directly below the microvillous border. Cytoplasmic blebs 
also arose from the cell membranes and were extruded into 
the tubular lumens. 
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Fig 1. Graphic representatIOn of serum creannlne levels In 
high-dose FK 506- and evA-treated animals. Results are ex· 
pressed as mean !: SEM. 
Animals treated with 25 mgikg/d Cy A showed a marked 
increase in cytoplasmic vacuolization. with involvement of 
both the adluminal and basal aspects of cytoplasm by this 
process. In addition. there was frequent coalescence of 
vacuoles to form large, space-occupying structures that 
appeared to have rent the cytoplasm apart. 
FK 506-treated animals showed slightly more cytoplas-
mic vacuolization than did controls. but noticeably less 
than CyA animals. In the FK 506 group. the majority of 
cytoplasmic vacuoles were located in the luminal half of 
the cell. and coalescence was seen only rarely as compared 
with eyA animals. 
The difference among groups was also apparent at the 
level of thick (I p.m) plastic-embedded sections. 
Cytoplasmic vacuolization persisted in all groups at day 
5. At this time. more electron-dense material was seen in a 
number of vacuoles. in either an amorphous or myelin 
configuration. CyA and FK 506. but not control animals. 
also showed marked heterogeneity in the size of mitochon-
dria. including enlarged forms (megarnitochondrial. Many 
vacuoles appeared to be distoning and possibly disrupting 
mitochondria. At the I /-Lm level. FK 506 animals appeared 
to have more tubular cytoplasmic vacuolization than at 
day 2. However. this did not approach the degree of cell 
disruption observed in CyA animals at day 2. By light 
microscopy. both FK 506 and control animals showed a 
moderate degree of tubular cytoplasmic basophilia in ar-
eas. This was not as prominent in Cy A animals. in whom 
the tubular cells had a more eosinophilic and generally 
swollen appearance. 
At day 10. experimental animals showed increased tu-
bular basophilia. tubular dilation. and evidence of individ· 
ual degenerated tubular cells compared with controls. No 
clear-cut differences could be discerned among the various 
experimental groups . 
DISCUSSION 
FK 506 is the forerunner of a new class of immunosup-
pressants that combines high efficacy with a low incidence 
of side effects. in both clinical and animal studies to date 
(Starzl. this issue). However. since the mode of therapeu· 
tic action appears similar to that of eVA. we were 
prompted to ask whether or not FK 506 would show any 
evidence of similar toxicity under specific experimental 
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conditions. We chose to examine this question in the 
setting of renal ischemia. since it is known that Cy A plus 
ischemia act synergistically to cause acute renal damage. 
Our findings indicate that FK 506 does cause acute 
tubular alterations In a rat model of renal ischemia. The 
ultrastructural observations of cytoplasmic vacuolization 
and megamitochondria are similar to those changes de-
scribed for CyA-induced ischemia renal damage. 
Cy A at 25 mg/kg/d was associated with higher elevations 
of BUN and creatinine at I and 2 days than was FK 506 at 
4 mglkg/d. This coincided with more severe ultrastructural 
changes in the renal tubular cells of Cy A-treated animals at 
this time. At lower doses. there was no discernible differ-
ence between the creatinine levels of experimental groups 
treated with either drug. Serum enzyme values in all 
groups descended toward baseline by day 10. consistent 
with a reversible toxic reaction. 
The combination of CyA. \0 mglkgld. and FK 506. I 
mg/kgld. resulted in higher early serum BUN and creati-
nine values than did treatment with either agent alone at 
these doses. Thus. there is at least an additive toxicity of 
the two agents under these conditions. 
These observations. if translated literally. have interest-
ing implications in the clinical situation. First. the doses of 
FK 506 used in this study are several lOO-fold more 
immunosuppressive in humans than are the doses ofCyA. 
Thus. although the mechanism of action on the ischemic 
kidney appears similar. the study suggests that such acute 
nephrotoxicity might be subclinical to non-existent in FK 
506-treated patients. except under extreme circumstances. 
Second, the additive effects of FK 506 and CyA on 
ischemic kidneys imply that induction of immunosuppres-
sion with FK 506 alone may be easier than with combina-
89 
tion FK 506 and CyA. Third. this study suggests that 
switching a patient from CyA to FK 506 could be associ-
ated with an acute reversible renal toxicity. which would 
subside as Cy A was eliminated from the system. Finally. 
the results raise the hope that FK 506 may also be found to 
be less nephrotoxic than Cy A in the chronic setting. 
Long-term studies are indicated to explore this possibility. 
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